Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janet K Coller

Showing results (11-20 of 66) with videos related to

Pageof 7
Sort By:
Breast Cancer Research and Treatment|November 29, 2007
TGFbeta2 and TbetaRII are valid molecular biomarkers for the antiproliferative effects of tamoxifen and tamoxifen metabolites in breast cancer cellsMiriam B Buck, Janet K Coller, Thomas E Mürdter, et al.
British Journal of Clinical Pharmacology|June 21, 2019
The impact of liver transplant recipient and donor genetic variability on tacrolimus exposure and transplant outcomeJanet K Coller, Jeyamani Ramachandran, Libby John, et al.
Brain, Behavior, and Immunity|March 31, 2011
Naloxone-precipitated morphine withdrawal behavior and brain IL-1β expression: comparison of different mouse strainsLiang Liu, Janet K Coller, Linda R Watkins, et al.
Pharmacogenetics and Genomics|November 30, 2018
Effect of tacrolimus dispositional genetics on acute rejection in the first 2 weeks and estimated glomerular filtration rate in the first 3 months following kidney transplantationRong Hu, Daniel T Barratt, Janet K Coller, et al.
Pharmacogenetics and Genomics|October 6, 2009
Association of IL-1B genetic polymorphisms with an increased risk of opioid and alcohol dependenceLiang Liu, Mark R Hutchinson, Jason M White, et al.
Therapeutic Drug Monitoring|July 2, 2019
Is There a Temporal Relationship Between Trough Whole Blood Tacrolimus Concentration and Acute Rejection in the First 14 Days After Kidney Transplantation?Rong Hu, Daniel T Barratt, Janet K Coller, et al.
Frontiers in Pharmacology|March 11, 2020
No Major Effect of Innate Immune Genetics on Acute Kidney Rejection in the First 2 Weeks Post-TransplantationRong Hu, Daniel T Barratt, Janet K Coller, et al.
Clinical Pharmacology and Therapeutics|December 21, 2006
ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individualsJanet K Coller, Daniel T Barratt, Karianne Dahlen, et al.
Basic & Clinical Pharmacology & Toxicology|April 1, 2018
CYP3A5*3 and ABCB1 61A>G Significantly Influence Dose-adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Post-Kidney TransplantationRong Hu, Daniel T Barratt, Janet K Coller, et al.
Journal of Cancer Research and Clinical Oncology|July 16, 2022
Contribution of TLR4 to colorectal tumor microenvironment, etiology and prognosisElise E Crame, Saeed Nourmohammadi, Hannah R Wardill, et al.
Pageof 7

Showing results (11-20 of 66) with videos related to

Sort By:
Pageof 7
Breast Cancer Research and Treatment|November 29, 2007
TGFbeta2 and TbetaRII are valid molecular biomarkers for the antiproliferative effects of tamoxifen and tamoxifen metabolites in breast cancer cellsMiriam B Buck, Janet K Coller, Thomas E Mürdter, et al.
British Journal of Clinical Pharmacology|June 21, 2019
The impact of liver transplant recipient and donor genetic variability on tacrolimus exposure and transplant outcomeJanet K Coller, Jeyamani Ramachandran, Libby John, et al.
Brain, Behavior, and Immunity|March 31, 2011
Naloxone-precipitated morphine withdrawal behavior and brain IL-1β expression: comparison of different mouse strainsLiang Liu, Janet K Coller, Linda R Watkins, et al.
Pharmacogenetics and Genomics|November 30, 2018
Effect of tacrolimus dispositional genetics on acute rejection in the first 2 weeks and estimated glomerular filtration rate in the first 3 months following kidney transplantationRong Hu, Daniel T Barratt, Janet K Coller, et al.
Pharmacogenetics and Genomics|October 6, 2009
Association of IL-1B genetic polymorphisms with an increased risk of opioid and alcohol dependenceLiang Liu, Mark R Hutchinson, Jason M White, et al.
Therapeutic Drug Monitoring|July 2, 2019
Is There a Temporal Relationship Between Trough Whole Blood Tacrolimus Concentration and Acute Rejection in the First 14 Days After Kidney Transplantation?Rong Hu, Daniel T Barratt, Janet K Coller, et al.
Frontiers in Pharmacology|March 11, 2020
No Major Effect of Innate Immune Genetics on Acute Kidney Rejection in the First 2 Weeks Post-TransplantationRong Hu, Daniel T Barratt, Janet K Coller, et al.
Clinical Pharmacology and Therapeutics|December 21, 2006
ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individualsJanet K Coller, Daniel T Barratt, Karianne Dahlen, et al.
Basic & Clinical Pharmacology & Toxicology|April 1, 2018
CYP3A5*3 and ABCB1 61A>G Significantly Influence Dose-adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Post-Kidney TransplantationRong Hu, Daniel T Barratt, Janet K Coller, et al.
Journal of Cancer Research and Clinical Oncology|July 16, 2022
Contribution of TLR4 to colorectal tumor microenvironment, etiology and prognosisElise E Crame, Saeed Nourmohammadi, Hannah R Wardill, et al.
Pageof 7